Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reaffirmed by equities research analysts at Credit Suisse Group in a report released on Thursday. They presently have a $82.00 target price on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would indicate a potential upside of 12.76% from the stock’s current price.

Several other equities research analysts have also recently weighed in on GILD. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Berenberg Bank reissued a “buy” rating and set a $86.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research report on Sunday, August 20th. Finally, Cowen reissued an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Thursday, August 31st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average target price of $85.11.

Shares of Gilead Sciences (GILD) traded down $0.57 during trading on Thursday, hitting $72.72. 5,584,081 shares of the stock were exchanged, compared to its average volume of 9,215,772. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a market cap of $95,736.46, a PE ratio of 7.65, a price-to-earnings-growth ratio of -1.23 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.75 EPS. analysts predict that Gilead Sciences will post 8.53 earnings per share for the current year.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last quarter, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in GILD. Keel Point LLC boosted its holdings in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the last quarter. Paradigm Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the last quarter. West Oak Capital LLC boosted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the last quarter. First Heartland Consultants Inc. boosted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC boosted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 41 shares during the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.

WARNING: “Credit Suisse Group Reaffirms “Buy” Rating for Gilead Sciences (GILD)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/07/credit-suisse-group-reaffirms-buy-rating-for-gilead-sciences-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.